Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Roche Holding AG (OTCQX International Premier:RHHBY)

32.27
Delayed Data
As of Jul 21
 +0.07 / +0.22%
Today’s Change
25.25
Today|||52-Week Range
36.82
+13.11%
Year-to-Date
Is a Beat in the Cards for ImmunoGen (IMGN) in Q2 Earnings?
Jul 21 / Zacks.com - Paid Partner Content
Mylan's Biosimilar Herceptin Gets FDA Advisory Committee Nod
Jul 17 / Zacks.com - Paid Partner Content
Puma's (PBYI) Breast Cancer Drug Neratinib Gets FDA Approval
Jul 18 / Zacks.com - Paid Partner Content
Why Are Shares of Exelixis (EXEL) Up 77% So Far in 2017?
Jul 13 / Zacks.com - Paid Partner Content
Novartis Tops Q2 Earnings, Sandoz Faces Pricing Pressure
Jul 18 / Zacks.com - Paid Partner Content
Alnylam (ALNY) Upgraded to Buy on Solid Pipeline Growth
Jul 12 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Infosys, Toyota Motor, Honda Motor, Taiwan Semicon...
Jul 18 / Zacks.com - Paid Partner Content
Roche (RHHBY) Announces Positive Data on Hemophilia A Drug
Jul 11 / Zacks.com - Paid Partner Content
AstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise
Jul 17 / Zacks.com - Paid Partner Content
BioLineRx/Roche Scan BL-8040-Tecentriq for Pancreatic Cancer
Jul 11 / Zacks.com - Paid Partner Content
Foreign Stock Roundup: Infosys Beats, Taiwan Semiconductor Misses
Jul 17 / Zacks.com - Paid Partner Content
Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx
Jul 11 / Zacks.com - Paid Partner Content